

Table 19.26
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes^a
SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2007-2016

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
Lymphoid Neoplasm	37.2	452,924	-0.5*	6.2	18,862	0.4	24.7	189,692	-0.5*	165.7	244,370	-0.5
1 Hodgkin Lymphoma	2.8	32,262	-1.7*	1.3	3,927	-0.6	3.3	22,556	-1.5*	3.9	5,779	-3.1*
2 Non-Hodgkin lymphoma	33.6	409,991	-0.3	4.8	14,693	0.4	21.0	163,591	-0.3	157.2	231,707	-0.4
2(a) Non-Hodgkin lymphoma, B-cell	31.1	380,349	-0.1	3.9	11,836	1.4*	19.0	148,768	-0.2	149.1	219,745	-0.2
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	1.5	16,631	2.0*	3.1	9,416	1.0	0.7	5,203	3.9*	1.4	2,012	2.5
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	28.0	343,965	-0.4*	0.7	2,271	3.0*	17.4	137,225	-0.5*	138.7	204,469	-0.4
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	6.9	85,601	-1.3*	0.0	35	-	3.5	29,103	-1.1*	38.2	56,463	-1.4*
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	6.1	75,061	-1.5*	0.0	30	-	3.1	25,339	-1.3*	33.6	49,692	-1.7*
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	0.0	311	1.9	-	-	-	0.0	72	-	0.2	234	2.6
2(a) 2.1.3. Mantle-cell lymphoma	0.8	10,229	0.3	-	-	-	0.4	3,692	0.2	4.4	6,537	0.4
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	0.7	8,651	0.0	-	-	-	0.3	2,590	-1.1	4.1	6,059	0.4
2(a) 2.2.1. Lymphoplasmacytic lymphoma	0.3	3,667	-0.3	-	-	-	0.1	1,132	-1.8	1.7	2,533	0.2
2(a) 2.2.2. Waldenstrom macroglobulinemia	0.4	4,984	0.3	-	-	-	0.2	1,458	-0.7	2.4	3,526	0.6
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	7.2	87,188	0.0	0.3	925	2.6	4.8	36,480	-0.2	33.9	49,783	0.2
2(a) 2.3.1. DLBCL, NOS ^c	7.1	85,899	-0.1	0.3	861	1.2	4.6	35,469	-0.5	33.7	49,569	0.1
2(a) 2.3.2. Intravascular large B-cell lymphoma	0.0	162	-	-	-	-	0.0	63	-	0.1	99	-
2(a) 2.3.3. Primary effusion lymphoma	0.0	181	2.7	-	-	-	0.0	126	-	0.0	55	-
2(a) 2.3.4. Mediastinal large B-cell lymphoma	0.1	946	11.6*	0.0	64	-	0.1	822	11.1*	0.0	60	-
2(a) 2.4. Burkitt lymphoma/leukemia	0.4	4,692	-2.6*	0.3	1,028	3.2*	0.4	2,618	-4.3*	0.7	1,046	-4.3*
2(a) 2.5. Marginal-zone lymphoma (MZL)	2.2	26,534	0.0	0.0	137	1.3	1.4	11,049	0.5	10.4	15,348	-0.4
2(a) 2.5.1. Splenic MZL	0.2	2,418	0.4	-	-	-	0.1	889	-0.8	1.0	1,529	1.0
2(a) 2.5.2. Extranodal MZL, MALT ^c type	1.3	15,979	0.6	0.0	92	-	0.9	7,148	1.1	5.9	8,739	0.3
2(a) 2.5.3. Nodal MZL	0.7	8,137	-1.5	0.0	45	-	0.4	3,012	-0.5	3.4	5,080	-2.0
2(a) 2.6. Follicular lymphoma	3.5	43,582	-2.1*	0.0	119	-	2.8	21,725	-2.5*	14.7	21,738	-1.8*
2(a) 2.7. Hairy-cell leukemia	0.3	3,712	-1.6*	-	-	-	0.3	2,311	-1.9*	0.9	1,401	-1.2
2(a) 2.8. Plasma cell neoplasms	6.8	83,957	0.8*	0.0	24	-	3.9	31,325	1.2*	35.8	52,608	0.6
2(a) 2.8.1. Plasmacytoma	0.4	4,879	-0.4	0.0	16	-	0.3	2,362	-0.6	1.7	2,501	-0.3
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	6.4	79,078	0.9*	-	-	-	3.6	28,963	1.4*	34.1	50,107	0.7
2(a) 2.9. Heavy chain disease	0.0	48	-	-	-	-	0.0	24	-	0.0	23	-
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS ^c	1.6	19,753	3.3*	0.0	149	2.7	0.8	6,340	3.7*	9.0	13,264	3.2

The APC is the Annual Percent Change over the time interval.

^a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.

Table 19.26 - continued
 All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes
 SEER^b Incidence Rates and Annual Percent Change by Age at Diagnosis

All Races, Both Sexes, 2007-2016

Site	All Ages			Ages 0-19			Ages 20-64			Ages 65+		
	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC	Rate	Count	APC
2(b) Non-Hodgkin lymphoma, T-cell	2.3	27,222	0.1	0.8	2,502	1.8	1.9	13,933	0.3	7.3	10,787	-0.6
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	0.1	616	-	0.1	293	-	0.0	272	-	0.0	51	-
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	2.2	26,531	1.1	0.7	2,207	7.5*	1.9	13,621	1.2*	7.3	10,703	-0.4
2(b) 2.1. Mycosis fungoides/Sezary syndrome	0.6	6,969	1.8*	0.1	213	8.4*	0.6	4,080	2.3*	1.8	2,676	0.5
2(b) 2.1.1. Mycosis fungoides	0.6	6,739	1.7*	0.1	213	8.4*	0.5	3,990	2.2*	1.7	2,536	0.4
2(b) 2.1.2. Sezary syndrome	0.0	230	4.6	-	-	-	0.0	90	-	0.1	140	-
2(b) 2.2. Peripheral T-cell lymphoma	1.2	14,531	-1.0	0.2	534	0.7	1.0	7,159	-0.9	4.6	6,838	-1.2
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS ^c	0.4	5,393	-0.1	0.0	86	-	0.3	2,489	0.4	1.9	2,818	-0.4
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	0.2	1,902	0.2	-	-	-	0.1	699	-0.9	0.8	1,201	0.7
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	0.0	176	4.4*	0.0	31	-	0.0	111	-	0.0	34	-
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	0.2	2,523	-3.6*	0.1	291	0.0	0.2	1,450	-3.3*	0.5	782	-5.4*
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	0.0	139	-	-	-	-	0.0	98	-	0.0	28	-
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	0.0	186	-0.2	-	-	-	0.0	84	-	0.1	101	-
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS ^c	0.2	2,963	-0.7	0.0	59	-	0.2	1,575	0.1	0.9	1,329	-1.4
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	0.1	1,249	-4.1*	0.0	51	-	0.1	653	-4.9*	0.4	545	-3.9*
2(b) 2.3. Adult T-cell leukemia/lymphoma	0.3	3,417	9.6*	0.5	1,428	10.1*	0.2	1,474	9.9*	0.3	515	6.7*
2(b) 2.4. NK ^c /T-cell lymphoma, nasal-type/aggressive NK ^c -cell leukemia	0.1	985	0.2	0.0	26	-	0.1	659	0.0	0.2	300	0.5
2(b) 2.5. T-cell large granular lymphocytic leukemia	0.0	120	-	-	-	-	0.0	54	-	0.0	65	-
2(b) 2.6. Prolymphocytic leukemia, T-cell	0.0	509	3.0	-	-	-	0.0	195	-0.5	0.2	309	4.4*
2(b) 3. Non-Hodgkin lymphoma, NOS ^c , T-cell	0.0	75	-	-	-	-	0.0	40	-	0.0	33	-
2(c) Non-Hodgkin lymphoma, unknown lineage	0.2	2,420	-27.4*	0.1	355	-	0.1	890	-21.6*	0.8	1,175	-27.9*
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	0.1	814	-28.3*	0.1	343	-	0.0	238	-	0.2	233	-
2(c) 2. Prolymphocytic leukemia, unknown lineage	0.0	95	-	-	-	-	0.0	25	-	0.0	69	-
2(c) 3. Non-Hodgkin lymphoma, NOS ^c , unknown lineage	0.1	1,511	-27.4*	-	-	-	0.1	627	-20.2*	0.6	873	-31.9*
2(*) 1. Total precursor lymphoma/leukemia ^d	1.6	18,061	-0.7	3.3	10,052	-1.5*	0.8	5,713	0.6	1.5	2,296	-0.1
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	0.1	762	27.3*	0.0	20	-	0.0	339	22.7*	0.3	403	-
4 Lymphoid neoplasm, NOS ^c	0.8	9,909	-5.5*	0.1	222	11.3*	0.4	3,206	-5.9*	4.3	6,481	-5.9*

The APC is the Annual Percent Change over the time interval.

^a Morton LM, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

^b SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

^d Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval.

Trend based on less than 10 cases for at least one year within the time interval.